Pinealon
NeuroprotectionNeurology research on Pinealon examines whether this khavinson tripeptide (pineal-derived) produces measurable CNS effects beyond peripheral activity. The cognitive case rests on three convergent threads: penetrates cells, enters the nucleus, and modulates gene expression reduces apoptosis in stress conditions. protects neurons from glutamate excitotoxicity. part of the broader khavinson bioregulator framework where short peptides serve as tissue-specific transcriptional regulators.; downstream consequences for monoamine and neurotrophic signalling; and reduction of chronic neuroinflammation. Pinealon is dosed at 5-10 mg 1x daily for 10-20 day cycles via subq/intranasal in cognitive-focused protocols, with the Short plasma; durable tissue effects pharmacokinetic profile shaping receptor occupancy timing.
Key Takeaways
Cognitive lens: Pinealon acts as a restorative compound rather than a stimulant for cognitive endpoints. CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects. Mechanism: Penetrates cells, enters the nucleus, and modulates gene expression. Neuro dose: 5-10 mg 1x daily for 10-20 day cycles via subq/intranasal; cognitive effects accumulate across 4-8 weeks. Cognitive stack partners: Semax, Selank, Semax + Selank Blend.
Three pathways shape Pinealon's cognitive profile: Penetrates cells, enters the nucleus, and modulates gene expression. Reduces apoptosis in stress conditions. Protects neurons from glutamate excitotoxicity. Part of the broader Khavinson bioregulator framework where short peptides serve as tissue-specific transcriptional regulators. Each subsection below covers one - CNS access mechanisms, neurotrophic and monoamine effects, and the inflammation-and-recovery layer that often produces the most subjectively reported cognitive shifts.
Cerebral perfusion and the structural cognitive substrate
Cognitive function depends on adequate cerebral perfusion, intact endothelial signalling, and a low chronic-inflammatory tone in the brain parenchyma. Pinealon, with its Penetrates cells, enters the nucleus, and modulates gene expression Reduces apoptosis in stress conditions. Protects neurons from glutamate excitotoxicity. Part of the broader Khavinson bioregulator framework where short peptides serve as tissue-specific transcriptional regulators. mechanism, contributes to this substrate rather than producing acute stimulant-like activation. Across the cognitive applications outlined below, what users describe is restoration of baseline rather than amplification above it. The Short plasma; durable tissue effects pharmacokinetic profile supports this restorative rather than stimulant phenotype.
Inflammation and neurological recovery
One of the most replicated effects across compounds in Pinealon's class (Khavinson tripeptide (pineal-derived)) is reduction of inflammatory cytokines (TNF-α, IL-1β, IL-6) in tissues including the central nervous system. For users whose cognitive complaints track with chronic low-grade neuroinflammation — long-COVID, post-viral cognitive fog, post-concussion lingering symptoms, chronic stress — this anti-inflammatory layer is often the most operationally relevant mechanism. Pinealon's contribution operates on the same axis at 5-10 mg per dose.
Receptor pharmacology and selectivity profile
Pinealon's receptor-level pharmacology determines its selectivity profile and its overlap with companion peptides. Penetrates cells, enters the nucleus, and modulates gene expression. Reduces apoptosis in stress conditions. Protects neurons from glutamate excitotoxicity. Part of the broader Khavinson bioregulator framework where short peptides serve as tissue-specific transcriptional regulators. The selectivity (or lack thereof) for the principal target relative to off-target receptors is the basis for both the clinical phenotype and the side-effect profile. In stack design this matters: pairing Pinealon with peptides engaging the same primary receptor produces competition rather than synergy.
For post-tbi recovery, Pinealon is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.
Where Pinealon is used for stroke recovery, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
Mood Stabilisation is one of the more-reported subjective benefits of Pinealon across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.
For anxiety, Pinealon is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 5-10 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 3-10 mg | 4–6 weeks initial cycle |
| Neuroprotection focus | SubQ | 5-10 mg | 1x daily for 10-20 day cycles |
| Maintenance phase | SubQ | 4-10 mg | Ongoing with periodic pauses |
Dose timing for Pinealon is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Pinealon stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.
- Pinealon + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with Pinealon's mechanism in cognitive / neurological protocols.
- Pinealon + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with Pinealon's mechanism in cognitive / neurological protocols.
- Pinealon + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with Pinealon's mechanism in cognitive / neurological protocols.
- Pinealon + DSIP: Mechanism remains incompletely characterised. Pairs naturally with Pinealon's mechanism in cognitive / neurological protocols.
Excellent. Decades of safety data in Russian research.
Lens-specific safety considerations for cognitive / neurological use of Pinealon: Excellent. Decades of safety data in Russian research. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Pinealon | Khavinson tripeptide (pineal-derived) | Short plasma; durable tissue effects | Neuroprotection |
| Semax | ACTH-derived nootropic heptapeptide | CNS effect hours; plasma minutes | A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent |
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder |
| DSIP | Neuropeptide (sleep) | ~7 min plasma; CNS effects longer | A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience |
Does Pinealon cross the blood-brain barrier?
How long until I notice cognitive effects?
Is Pinealon a true nootropic?
Is Pinealon appropriate alongside SSRIs or other psychiatric medications?
What is the regulatory status of Pinealon?
What should I look for in Pinealon sourcing and quality?
Start a Pinealon Protocol
Alukard provides physician-supervised cognitive protocols with GMP-certified Pinealon and GMP-certified compounds and comprehensive neurological assessments.
Get ProtocolQuick Facts
- Molecular weight
- 418 Da
- Sequence length
- 3 aa
- Half-life
- Short plasma; durable tissue effects
- WADA
- Not on prohibited list
- FDA
- Unapproved
- Research
- Russian clinical trials; limited Western data
Stack Partners
All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Pinealon unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Cognitive / Neurological Protocol for Pinealon
Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.
HIPAA Compliant · GMP Certified · Physician Supervised